A citation-based method for searching scientific literature

Fabrice Andre, Maria V Dieci, Peter Dubsky, Christos Sotiriou, Giuseppe Curigliano, Carsten Denkert, Sherene Loi. Clin Cancer Res 2013
Times Cited: 144







List of co-cited articles
641 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.
Carsten Denkert, Sibylle Loibl, Aurelia Noske, Marc Roller, Berit Maria Müller, Martina Komor, Jan Budczies, Silvia Darb-Esfahani, Ralf Kronenwett, Claus Hanusch,[...]. J Clin Oncol 2010
41

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.
S Loi, S Michiels, R Salgado, N Sirtaine, V Jose, D Fumagalli, P-L Kellokumpu-Lehtinen, P Bono, V Kataja, C Desmedt,[...]. Ann Oncol 2014
796
34

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.
R Salgado, C Denkert, S Demaria, N Sirtaine, F Klauschen, G Pruneri, S Wienert, G Van den Eynden, F L Baehner, F Penault-Llorca,[...]. Ann Oncol 2015
31

Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.
Sherene Loi, Nicolas Sirtaine, Fanny Piette, Roberto Salgado, Giuseppe Viale, Françoise Van Eenoo, Ghizlane Rouas, Prudence Francis, John P A Crown, Erika Hitre,[...]. J Clin Oncol 2013
28

Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.
Sylvia Adams, Robert J Gray, Sandra Demaria, Lori Goldstein, Edith A Perez, Lawrence N Shulman, Silvana Martino, Molin Wang, Vicky E Jones, Thomas J Saphner,[...]. J Clin Oncol 2014
775
21

Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.
Carsten Denkert, Gunter von Minckwitz, Jan C Brase, Bruno V Sinn, Stephan Gade, Ralf Kronenwett, Berit M Pfitzner, Christoph Salat, Sherene Loi, Wolfgang D Schmitt,[...]. J Clin Oncol 2015
648
21

Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer.
Sahar M A Mahmoud, Emma Claire Paish, Desmond G Powe, R Douglas Macmillan, Matthew J Grainge, Andrew H S Lee, Ian O Ellis, Andrew R Green. J Clin Oncol 2011
929
20

Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
Roberto Salgado, Carsten Denkert, Christine Campbell, Peter Savas, Paolo Nuciforo, Claudia Aura, Evandro de Azambuja, Holger Eidtmann, Catherine E Ellis, Jose Baselga,[...]. JAMA Oncol 2015
359
18

Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study.
M V Dieci, C Criscitiello, A Goubar, G Viale, P Conte, V Guarneri, G Ficarra, M C Mathieu, S Delaloge, G Curigliano,[...]. Ann Oncol 2014
233
16


Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer.
Nathan R West, Katy Milne, Pauline T Truong, Nicol Macpherson, Brad H Nelson, Peter H Watson. Breast Cancer Res 2011
266
13


Molecular portraits of human breast tumours.
C M Perou, T Sørlie, M B Eisen, M van de Rijn, S S Jeffrey, C A Rees, J R Pollack, D T Ross, H Johnsen, L A Akslen,[...]. Nature 2000
11

Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer.
Elena García-Martínez, Ginés Luengo Gil, Asunción Chaves Benito, Enrique González-Billalabeitia, María Angeles Vicente Conesa, Teresa García García, Elisa García-Garre, Vicente Vicente, Francisco Ayala de la Peña. Breast Cancer Res 2014
157
11

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph P Costantino, Norman Wolmark, Hervé Bonnefoi, David Cameron, Luca Gianni, Pinuccia Valagussa,[...]. Lancet 2014
11

Clinical relevance of host immunity in breast cancer: from TILs to the clinic.
Peter Savas, Roberto Salgado, Carsten Denkert, Christos Sotiriou, Phillip K Darcy, Mark J Smyth, Sherene Loi. Nat Rev Clin Oncol 2016
447
11

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
Brian D Lehmann, Joshua A Bauer, Xi Chen, Melinda E Sanders, A Bapsi Chakravarthy, Yu Shyr, Jennifer A Pietenpol. J Clin Invest 2011
10

Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.
Edith A Perez, E Aubrey Thompson, Karla V Ballman, S Keith Anderson, Yan W Asmann, Krishna R Kalari, Jeanette E Eckel-Passow, Amylou C Dueck, Kathleen S Tenner, Jin Jen,[...]. J Clin Oncol 2015
140
10

The immune system and response to HER2-targeted treatment in breast cancer.
Giampaolo Bianchini, Luca Gianni. Lancet Oncol 2014
173
10

Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients.
H R Ali, E Provenzano, S-J Dawson, F M Blows, B Liu, M Shah, H M Earl, C J Poole, L Hiller, J A Dunn,[...]. Ann Oncol 2014
435
10

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.
Lionel Apetoh, François Ghiringhelli, Antoine Tesniere, Michel Obeid, Carla Ortiz, Alfredo Criollo, Grégoire Mignot, M Chiara Maiuri, Evelyn Ullrich, Patrick Saulnier,[...]. Nat Med 2007
10

Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.
Edith A Perez, Karla V Ballman, Kathy S Tenner, E Aubrey Thompson, Sunil S Badve, Helen Bailey, Frederick L Baehner. JAMA Oncol 2016
136
10

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.
Christina Curtis, Sohrab P Shah, Suet-Feung Chin, Gulisa Turashvili, Oscar M Rueda, Mark J Dunning, Doug Speed, Andy G Lynch, Shamith Samarajiwa, Yinyin Yuan,[...]. Nature 2012
9

CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer.
Shuzhen Liu, Jonathan Lachapelle, Samuel Leung, Dongxia Gao, William D Foulkes, Torsten O Nielsen. Breast Cancer Res 2012
286
9

Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis.
Michail Ignatiadis, Sandeep K Singhal, Christine Desmedt, Benjamin Haibe-Kains, Carmen Criscitiello, Fabrice Andre, Sherene Loi, Martine Piccart, Stefan Michiels, Christos Sotiriou. J Clin Oncol 2012
171
9

Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.
Makiko Ono, Hitoshi Tsuda, Chikako Shimizu, Sohei Yamamoto, Tatsuhiro Shibata, Harukaze Yamamoto, Taizo Hirata, Kan Yonemori, Masashi Ando, Kenji Tamura,[...]. Breast Cancer Res Treat 2012
203
9

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.
Jérôme Galon, Anne Costes, Fatima Sanchez-Cabo, Amos Kirilovsky, Bernhard Mlecnik, Christine Lagorce-Pagès, Marie Tosolini, Matthieu Camus, Anne Berger, Philippe Wind,[...]. Science 2006
9

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
Cornelia Liedtke, Chafika Mazouni, Kenneth R Hess, Fabrice André, Attila Tordai, Jaime A Mejia, W Fraser Symmans, Ana M Gonzalez-Angulo, Bryan Hennessy, Marjorie Green,[...]. J Clin Oncol 2008
9

Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer.
S Muenst, A R Schaerli, F Gao, S Däster, E Trella, R A Droeser, M G Muraro, P Zajac, R Zanetti, W E Gillanders,[...]. Breast Cancer Res Treat 2014
379
9

Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial.
Yasmin Issa-Nummer, Silvia Darb-Esfahani, Sibylle Loibl, Georg Kunz, Valentina Nekljudova, Iris Schrader, Bruno Valentin Sinn, Hans-Ullrich Ulmer, Ralf Kronenwett, Marianne Just,[...]. PLoS One 2013
148
9

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Carsten Denkert, Gunter von Minckwitz, Silvia Darb-Esfahani, Bianca Lederer, Barbara I Heppner, Karsten E Weber, Jan Budczies, Jens Huober, Frederick Klauschen, Jenny Furlanetto,[...]. Lancet Oncol 2018
792
9

Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.
David G DeNardo, Donal J Brennan, Elton Rexhepaj, Brian Ruffell, Stephen L Shiao, Stephen F Madden, William M Gallagher, Nikhil Wadhwani, Scott D Keil, Sharfaa A Junaid,[...]. Cancer Discov 2011
8

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
8

In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas.
Kurt A Schalper, Vamsidhar Velcheti, Daniel Carvajal, Hallie Wimberly, Jason Brown, Lajos Pusztai, David L Rimm. Clin Cancer Res 2014
344
8

Prognostic and predictive value of PDL1 expression in breast cancer.
Renaud Sabatier, Pascal Finetti, Emilie Mamessier, José Adelaide, Max Chaffanet, Hamid Raza Ali, Patrice Viens, Carlos Caldas, Daniel Birnbaum, François Bertucci. Oncotarget 2015
320
8

Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy.
S Demaria, M D Volm, R L Shapiro, H T Yee, R Oratz, S C Formenti, F Muggia, W F Symmans. Clin Cancer Res 2001
224
8

PD-L1 expression in triple-negative breast cancer.
Elizabeth A Mittendorf, Anne V Philips, Funda Meric-Bernstam, Na Qiao, Yun Wu, Susan Harrington, Xiaoping Su, Ying Wang, Ana M Gonzalez-Angulo, Argun Akcakanat,[...]. Cancer Immunol Res 2014
707
8

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
Julie R Brahmer, Scott S Tykodi, Laura Q M Chow, Wen-Jen Hwu, Suzanne L Topalian, Patrick Hwu, Charles G Drake, Luis H Camacho, John Kauh, Kunle Odunsi,[...]. N Engl J Med 2012
8


CD4⁺ follicular helper T cell infiltration predicts breast cancer survival.
Chunyan Gu-Trantien, Sherene Loi, Soizic Garaud, Carole Equeter, Myriam Libin, Alexandre de Wind, Marie Ravoet, Hélène Le Buanec, Catherine Sibille, Germain Manfouo-Foutsop,[...]. J Clin Invest 2013
556
8

Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse.
Gaynor J Bates, Stephen B Fox, Cheng Han, Russell D Leek, José F Garcia, Adrian L Harris, Alison H Banham. J Clin Oncol 2006
806
8

T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers.
Achim Rody, Uwe Holtrich, Laos Pusztai, Cornelia Liedtke, Regine Gaetje, Eugen Ruckhaeberle, Christine Solbach, Lars Hanker, Andre Ahr, Dirk Metzler,[...]. Breast Cancer Res 2009
299
8

The immune contexture in human tumours: impact on clinical outcome.
Wolf Herman Fridman, Franck Pagès, Catherine Sautès-Fridman, Jérôme Galon. Nat Rev Cancer 2012
8

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.
Rita Nanda, Laura Q M Chow, E Claire Dees, Raanan Berger, Shilpa Gupta, Ravit Geva, Lajos Pusztai, Kumudu Pathiraja, Gursel Aktan, Jonathan D Cheng,[...]. J Clin Oncol 2016
879
8

Cancer immunoediting: from immunosurveillance to tumor escape.
Gavin P Dunn, Allen T Bruce, Hiroaki Ikeda, Lloyd J Old, Robert D Schreiber. Nat Immunol 2002
8




Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
Gunter von Minckwitz, Michael Untch, Jens-Uwe Blohmer, Serban D Costa, Holger Eidtmann, Peter A Fasching, Bernd Gerber, Wolfgang Eiermann, Jörn Hilfrich, Jens Huober,[...]. J Clin Oncol 2012
7

PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer.
Hallie Wimberly, Jason R Brown, Kurt Schalper, Herbert Haack, Matthew R Silver, Christian Nixon, Veerle Bossuyt, Lajos Pusztai, Donald R Lannin, David L Rimm. Cancer Immunol Res 2015
247
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.